Medicare Part D Complete Guide 2026

Part D is Medicare's prescription drug coverage. That's the short version. The longer version is that it's a voluntary but extremely consequential benefit that can either save you thousands of dollars a year or cost you a permanent monthly penalty for the rest of your life if you ignore it at the wrong time.

Here's what most people don't understand going in: Part D isn't administered by Medicare directly. You get it through private insurance companies—either as a standalone Prescription Drug Plan (PDP) if you have Original Medicare, or embedded inside a Medicare Advantage (MA-PD) plan. Medicare sets the rules. The private insurers compete within those rules. Your job is to pick the right plan for your specific drug list, in your specific zip code, at your specific pharmacies.

Sounds simple. It is not simple.

In 2026, there are roughly 360 standalone PDPs available nationally—down 22% from 464 plans in 2025. The market is consolidating fast. Five companies—Aetna, Health Care Service Corporation, Humana, UnitedHealthcare, and Wellcare—now account for 94% of all standalone PDPs. That concentration matters because it means less price competition, though the Inflation Reduction Act changes have actually pushed premiums down for many enrollees this year.

The 2026 base beneficiary premium is $38.99 per month. But here's the thing: that number is almost meaningless for your actual decision. The plan you choose will have its own premium, which can range from literally $0 to over $100 per month depending on where you live and what drugs you take. The $38.99 figure is the weighted average of all Part D premiums nationally—it's an anchor number for policy discussions, not your actual bill.

What actually matters for your wallet: the deductible, the formulary tier your drugs land on, which pharmacies are preferred, and whether your total spending will hit the $2,100 out-of-pocket cap. We're going to walk through all of it.

For 2026, Medicare restructured Part D into three coverage phases as part of the ongoing Inflation Reduction Act implementation. The old four-phase structure (deductible → initial coverage → coverage gap/donut hole → catastrophic) got simplified. The coverage gap is functionally gone. Here's how it actually works now.

**Phase 1: The Deductible**

The maximum deductible a Part D plan can charge in 2026 is $615. Not every plan charges the full deductible—some charge a partial deductible only on certain tiers, and some charge none at all (usually in exchange for a higher monthly premium or more restrictive formulary). If your plan has a deductible, you pay 100% of your drug costs until you've spent $615 out of pocket.

Quick example: You're on Eliquis (apixaban), which retails around $550-600 for a 30-day supply. One fill and you've essentially met your deductible. Someone on only generic metformin and lisinopril might not hit the deductible at all in a year.

Important distinction: the deductible applies to covered drugs on your plan's formulary. If you're filling a drug that's not on the formulary, that spending doesn't count toward anything—it's just money out of your pocket with no credit toward your cap.

**Phase 2: Initial Coverage (25% Coinsurance)**

Once you've met the deductible, you enter the initial coverage phase. In 2026, you pay 25% of the cost of your covered drugs—both brand-name and generic—until your total true out-of-pocket costs (TrOOP) reach $2,100.

This is flatter than the old structure. Before the IRA, initial coverage had one cost-sharing level and then you fell into the donut hole with different cost-sharing. Now it's a continuous 25% all the way to the cap. Cleaner. Still expensive if you're on expensive drugs, but at least predictable.

What counts toward TrOOP: your own payments, payments made by the Extra Help/LIS program, and payments from certain other sources like State Pharmaceutical Assistance Programs (SPAPs). What does NOT count: your premium payments, any amount paid by your plan, amounts paid by other insurance (like a retiree health plan), and—critically—anything you paid using a GoodRx coupon or manufacturer's discount coupon as a cash transaction outside of Medicare.

A real scenario: You're taking Xarelto (rivaroxaban), Jardiance (empagliflozin), and Ozempic (semaglutide). These are Tier 4-5 specialty drugs on most formularies. Each could cost you $150-500+ in coinsurance per fill depending on your plan's tier structure. You could hit $2,100 in three or four months. After that, everything is covered 100% for the rest of the year. That's the new Part D—designed to cap catastrophic spending.

**Phase 3: Catastrophic Coverage ($0 Out of Pocket)**

Once your TrOOP hits $2,100 in 2026, you pay nothing for the rest of the calendar year. Zero. Every covered drug on your formulary is free from that point until December 31st. This is the biggest change under the Inflation Reduction Act, and honestly it's a massive deal for anyone on expensive specialty medications.

In 2025 the cap was $2,000. It went up $100 for 2026. These small annual adjustments are written into the law, so the cap will continue to inch up over time—but the core protection remains.

The catastrophic phase resets every January 1st. No rollover. Whatever you spent in 2026 doesn't carry into 2027. You start the whole cycle over.

People keep asking variations of the same question: what exactly counts toward the $2,100? Let's be precise because the answer matters enormously.

**What counts toward your $2,100 TrOOP:**

— Your deductible payments (what you pay before coverage kicks in) — Your coinsurance or copays during the initial coverage phase — Payments made by Extra Help / Low Income Subsidy on your behalf — Payments from a State Pharmaceutical Assistance Program (SPAP)

**What does NOT count toward your $2,100 TrOOP:**

— Your monthly Part D premium (this never counts) — What your insurance plan pays (just your share counts) — Payments from another insurance plan, employer coverage, or Medicare Supplement — Cash payments using GoodRx or similar discount programs — Payments for drugs NOT on your plan's formulary — Payments for drugs in the deductible phase if your plan charges a partial deductible only on certain tiers—the math can get weird here

**Real dollar walkthrough for 2026:**

Let's say you're 68, on Original Medicare + a standalone PDP. Your drugs are metoprolol succinate (generic, Tier 1), atorvastatin (generic, Tier 1), and Eliquis (brand, Tier 3 on your plan). Your plan has the full $615 deductible, and your plan's coinsurance structure is: Tier 1 = $4 copay, Tier 3 = 40% coinsurance.

Months 1-2 (Deductible Phase): You fill Eliquis at full cost, roughly $300/fill. After two fills you've paid ~$600, deductible is met. The generics cost almost nothing at full price—$8-15 each—so those ate into the $615 too.

Months 2-11 (Initial Coverage): Eliquis at 40% coinsurance = ~$120/fill. Ten fills = ~$1,200 in Eliquis coinsurance. Add maybe $50-80 for the generics over those months. Total TrOOP after 11 months: roughly $615 (deductible) + $1,250 (coinsurance) = ~$1,865.

Month 12 (Approaching Cap): One more Eliquis fill puts you over $2,100. The moment your pharmacist's system registers the fill that crosses the $2,100 TrOOP threshold, you hit catastrophic. You might owe a prorated copay for that last fill—the plan calculates what you owed up to the cap and bills you only that. Everything after is $0.

For someone on Humira (adalimumab) or a targeted cancer drug at $8,000-15,000+ per fill, this cap is not theoretical. It's reached in January. That's what the IRA was designed for.

Every Part D plan has a formulary—a list of covered drugs organized into tiers. The tier determines your cost-sharing. Higher tier = higher out-of-pocket cost. This is one of the most important things to understand before picking a plan because the same drug can be Tier 3 on one plan and Tier 5 on another.

The standard five-tier structure most plans use:

**Tier 1 — Preferred Generics** Lowest cost. Usually a small copay of $0-$5. These are cheap generic drugs with multiple manufacturers, high availability, rock-solid safety records. Metformin, lisinopril, amlodipine, omeprazole, simvastatin, levothyroxine—the backbone of most people's drug cabinets. If all your drugs are Tier 1, honestly you don't need to stress much about plan selection. Pick the lowest premium and call it a day.

**Tier 2 — Non-Preferred Generics** Still generics but maybe newer to market, single-source, or the plan just decided to put them here. Copays typically $5-$15. Not a huge deal but worth checking. Sometimes your Tier 1 drug on Plan A is Tier 2 on Plan B.

**Tier 3 — Preferred Brand-Name Drugs** This is where costs start to sting. These are brand-name drugs the plan has negotiated better pricing on—they're on the formulary as preferred. Copays or coinsurance typically in the $35-$47 range, or 15-25% coinsurance. A lot of commonly used brand-name drugs land here: certain blood pressure meds, diabetes drugs that haven't gone generic yet, some inhalers.

**Tier 4 — Non-Preferred Drugs** Brand-name or high-cost generics that the plan didn't negotiate preferred status for. This is where things get expensive: 40-50% coinsurance on many plans. A drug that costs the plan $400/fill means you're paying $160-200 in coinsurance. Eliquis, Xarelto, Jardiance often land here on plans that don't have rebate arrangements with those manufacturers.

**Tier 5 — Specialty Drugs** The most expensive tier. These are biologics, specialty injectables, targeted cancer therapies, and high-cost specialty medications—think Humira, Ozempic/Wegovy (when covered), Revlimid, Tecfidera, Dupixent. Coinsurance is usually 25-33%. On a $15,000/month drug, that's $3,750-5,000 in coinsurance—except the $2,100 annual cap means you hit catastrophic coverage before the math gets catastrophic.

**The Exception: Tier 6 (Preferred Cost-Sharing / Select Care Tiers)**

Some plans add a Tier 6 for certain insulin products or generic drugs in enhanced benefit designs. As of 2026, insulin cost-sharing has been capped at $35/month for covered insulin products under the Inflation Reduction Act. Any covered insulin on any Part D plan costs you no more than $35 per 30-day supply, period. That's not negotiable—it's the law.

**How to Check Your Drug's Tier:**

Don't assume. Go to the plan's website or call them before enrolling. Also use Medicare Plan Finder at Medicare.gov and enter your specific drugs—it will show you exactly what tier each drug is on each plan and estimate your annual cost. That annual cost estimate is the number that matters, not the monthly premium.

Medicare Plan Finder is genuinely useful. A lot of people don't use it right, so let's go through it properly.

First: go to Medicare.gov/plan-compare. Not a third-party site, not an insurance company's site. The actual CMS tool. It's updated annually for each plan year.

Step 1: Set up your drug list. This is the most important step and where most people shortcut. Don't just enter your drug names—enter the exact dosage, form (tablet vs. extended release vs. injectable), and frequency. Atorvastatin 10mg vs. 40mg can be different tiers. Metformin 500mg vs. metformin ER 500mg can be different. Be precise.

Step 2: Enter your zip code. Part D plans are regional. The same plan name can have different formularies and different premiums in different parts of the country.

Step 3: Enter your preferred pharmacies. This matters more than most people realize. Part D plans have preferred pharmacy networks—using a preferred pharmacy can mean dramatically lower cost-sharing than using an out-of-network or non-preferred pharmacy. CVS might be preferred on Plan A but not on Plan B. Your local independent pharmacy might not be preferred on any plan.

Step 4: Look at the estimated annual drug cost column, not the monthly premium. I cannot stress this enough. A plan with a $4/month premium and a $615 deductible might cost you $1,800/year total. A plan with a $65/month premium and no deductible might cost you $1,200/year total. The annual total is what you're comparing.

Step 5: Check if the plan uses prior authorization, step therapy, or quantity limits on your drugs. The Plan Finder shows this. If your Tier 3 drug requires prior authorization on Plan A but not on Plan B, that's a meaningful practical difference—not just a cost difference.

Step 6: Look at the plan's star rating. CMS rates every Part D plan 1-5 stars based on drug safety, customer service, member experience, and plan responsiveness. Five-star plans can be joined at any time (not just during open enrollment). Plans with less than 3 stars for 3 consecutive years can be terminated. Stick to 3-star plans or better. Four and five stars are ideal.

Step 7: Check formulary stability. Has the plan changed its formulary significantly from the prior year? If your drugs were all covered last year on your current plan but you never re-evaluated, they might have moved tiers or been removed. Check every October during Open Enrollment (Oct 15 - Dec 7).

One more thing: if your plan sends you an Annual Notice of Change (ANOC) in September, read it. Actually read it. It will tell you every change to premiums, deductibles, and formulary tiers for the coming year. Most people throw it away. That's a mistake.

Fair warning: the 'best' plan depends entirely on your drugs, your zip code, and your pharmacies. There is no universally best plan. With that caveat firmly in place, here's an honest read on the major players in 2026.

**Wellcare — Best for Low Premiums**

Wellcare is consistently the most affordable option for beneficiaries with modest drug needs. Average premium around $8/month in many markets—compared to a national average closer to $40-60. Wellcare offers two main plans in 2026: Wellcare Classic and Wellcare Value Script. Government quality ratings are solid. The trade-off: formulary coverage can be thinner, and preferred pharmacy networks are narrower. If your drugs are mostly generic and you're okay with their pharmacy network, Wellcare is worth a serious look.

**Humana — Best for Avoiding Deductibles**

Humana has 51 plans nationally with $0 deductible. That's more zero-deductible options than any other carrier. Humana Basic Rx and Humana Premier Rx Plan have been consistent offerings since 2020, which signals stability. Humana tends to do well for people with brand-name drugs because their formulary negotiation has historically been strong. Also: Humana has a well-regarded mail-order pharmacy (Humana Pharmacy) with generous 90-day supply pricing. If you're worried about the $615 deductible erasing your budget in month one, Humana's worth checking specifically for that.

**UnitedHealthcare (AARP) — Best for Member Experience**

UHC's AARP-branded PDPs are among the most widely recognized and have consistently above-average member satisfaction. Higher premiums in most markets—often $40-80/month—but the pharmacy network is enormous and preferred pricing at major chains is strong. Their digital tools for drug management are also better than average. Good for someone who values customer service and broad pharmacy access over absolute lowest cost.

**SilverScript (Aetna/CVS) — Know What You're Getting**

SilverScript Choice is essentially the only surviving Aetna standalone PDP in 2026, a legacy product from the CVS Health acquisition. Premium averages around $69/month nationally—higher than most competitors. Full $615 deductible on all plans. Below-average member satisfaction scores. That said: if your drugs are primarily generic and you use CVS pharmacy, cost-sharing on Tier 1-2 drugs at CVS preferred pricing can be competitive. Just don't assume the SilverScript name means value in 2026.

**Health Care Service Corporation (HCSC) — Regional Player Worth Checking**

HCSC operates BCBS plans in Illinois, Texas, Oklahoma, New Mexico, and Montana. In those states, BCBS Part D plans can be surprisingly competitive, especially for beneficiaries with moderate drug complexity. Check if you're in those states.

**The Real Bottom Line on Plan Selection**

Run the numbers on Medicare.gov. Enter your drugs. In 2026 the market contracted significantly—22% fewer plans than 2025—but that doesn't mean you can't find good coverage. It means the winning move is to actually compare rather than auto-renew. Thirty minutes on Medicare Plan Finder beats every general recommendation in this article, because your drugs are your drugs.

This is one of the biggest structural decisions in Medicare, and it gets confused constantly. Let me be direct about what you're actually choosing between.

**Original Medicare + Standalone PDP**

You have Medicare Part A and Part B. You add a standalone Prescription Drug Plan (PDP). You might also have a Medicare Supplement (Medigap) policy to cover your Part A/B cost-sharing. This is the traditional Medicare approach.

Pros: You can see any doctor who accepts Medicare, anywhere in the country. No networks for medical care. You can switch Part D plans every year during Open Enrollment without affecting your medical coverage. Medigap premiums are predictable and benefits are standardized.

Cons: More expensive overall in most cases—paying for both a Medigap policy and a Part D plan. More moving parts. Medigap doesn't cover prescription drugs at all, which is why you need the PDP.

**Medicare Advantage with Embedded Drug Coverage (MA-PD)**

You join a Medicare Advantage plan (usually HMO or PPO) that includes Part D drug coverage built in. One card, one plan, usually lower or zero monthly premium.

Pros: Often $0 monthly premium. May include dental, vision, hearing benefits not in Original Medicare. Drug coverage is integrated—one plan to deal with.

Cons: Network restrictions—you generally have to use the plan's provider network for medical care. Prior authorization for medical services is common. Drug formularies on MA-PD plans can be different (sometimes better, sometimes worse) than standalone PDPs for your specific drugs. If you move or travel frequently, network restrictions can be a real problem.

**The Drug Coverage Comparison**

Here's what surprises people: Medicare Advantage drug formularies are not identical to standalone PDP formularies, even from the same insurance company. An Aetna MA-PD plan might have Tier 3 for Eliquis. The Aetna SilverScript standalone PDP might have Tier 4 for Eliquis. Same company, different formulary, different cost.

When you're evaluating MA-PD vs. standalone PDP, you must compare drug costs on both using Medicare Plan Finder—same drugs, same process. Don't assume MA-PD is better just because the premium is $0. And don't assume standalone PDP is better just because it's separate from managed care.

**If You're Sick and Expecting High Drug Costs**

The $2,100 out-of-pocket cap applies equally to MA-PD and standalone PDP plans. So for catastrophic drug spending, the cap protects you under both structures. The question becomes: what's your total cost before the cap? Run the numbers.

Extra Help—also called the Low Income Subsidy, or LIS—is the most underutilized Medicare benefit that exists. Millions of people qualify and don't know it. Let's fix that.

**What Extra Help Does**

Extra Help is a federal program that pays most or all of your Part D costs if you meet income and resource limits. We're talking: no deductible, no coverage gap (already eliminated), dramatically reduced copays, and protection from the late enrollment penalty. This is real money—CMS estimates the value at about $5,900 per year for full beneficiaries.

**2026 Income Limits for Extra Help**

To qualify for full Extra Help (100% LIS), your monthly income generally needs to be at or below: — Individual: approximately $1,680/month ($20,165/year) — Married couple: approximately $2,272/month ($27,265/year)

These are approximate figures based on 135% of the Federal Poverty Level. CMS adjusts them annually. The Social Security Administration confirms eligibility and uses your income from your most recent tax return or current income documentation.

For partial Extra Help (the old sliding scale), income can go somewhat higher—up to 150% FPL: — Individual: approximately $2,015/month ($24,185/year) — Married couple: approximately $2,725/month ($32,695/year)

**2026 Resource/Asset Limits**

Assets count too. For full Extra Help: — Individual: approximately $16,590 — Married couple: approximately $33,100

What counts as a resource: checking and savings accounts, stocks, bonds, IRAs, cash. What does NOT count: your primary residence (no matter what its value), one vehicle, personal belongings and household goods, life insurance policies with a combined face value under $1,500, and burial funds up to $1,500. The non-countable asset categories are more generous than many people expect.

**Automatic Enrollment in Extra Help**

You may be automatically enrolled if you already receive: — Medicaid (both Medicare and Medicaid = "dual eligible"—you get full Extra Help automatically) — Supplemental Security Income (SSI) — Medicare Savings Programs (QMB, SLMB, QI)

If you're automatically enrolled, Social Security will assign you to a benchmark Part D plan if you don't choose one yourself. These benchmark plans change annually. If you were auto-enrolled in a plan that went above the benchmark premium, you may have been moved—check your coverage.

**How to Apply**

Three ways:

1. Online at ssa.gov — takes about 20 minutes. Most direct path. 2. Call Social Security: 1-800-772-1213. They'll walk you through the application. 3. Visit your local Social Security office in person with documentation.

You'll need: proof of identity, Medicare card, information about your income (or most recent tax return), and documentation of your resources (bank statements are fine). State Medicaid offices can also process applications.

**What Extra Help Costs You in 2026**

If you qualify for full Extra Help: — Premium: $0 (you pay nothing if your plan is at or below the Low-Income Benchmark premium) — Deductible: $0 — Copays for generics: $1.10 (institutionalized) to $4.90 (non-institutionalized) — Copays for brand-name drugs: $1.10 to $12.15 depending on income level — After the catastrophic cap ($2,100): $0 for the rest of the year

If you have full Extra Help and you're also dual-eligible (Medicaid + Medicare), you're in the D-SNP world and your drug costs are essentially nothing for most standard medications.

**Don't Let the Application Scare You**

A lot of people eligible for Extra Help assume they won't qualify because they own their home or have some savings. The non-countable asset rules are more forgiving than you'd expect. Apply. The worst outcome is they say no. The best outcome is $5,900/year in drug cost relief.

This is the part of Medicare Part D that creates the most bitterness. People miss their enrollment window, figure they'll sign up 'whenever,' and then get hit with a penalty that follows them for life. Not exaggerating—for life, or at least as long as you have Part D coverage.

**The Basic Rule**

If you go without creditable prescription drug coverage for more than 63 consecutive days after your Initial Enrollment Period (IEP) ends, you owe a late enrollment penalty when you do enroll in Part D.

Your IEP is generally the 7-month window around your 65th birthday (3 months before the month you turn 65, your birthday month, and 3 months after). Miss this window and don't have creditable coverage elsewhere, the penalty clock starts.

**How the Penalty Is Calculated**

1% of the national base beneficiary premium ($38.99 in 2026) per month you were without coverage.

If you went 24 months without creditable coverage, your penalty is: 24 x 1% x $38.99 = 24 x $0.3899 = $9.36/month, rounded to the nearest $0.10 = $9.40/month permanently added to your premium.

That $9.40 gets added to whatever your chosen Part D plan charges. And it recalculates annually as the base beneficiary premium changes. So it's not a fixed $9.40 forever—it's 24% of the base premium forever. When the base premium goes up, your penalty goes up proportionally.

**What Counts as Creditable Coverage**

"Creditable" means coverage that's at least as good as standard Part D. Creditable coverage includes: — Employer-sponsored health insurance with prescription coverage (must be certified as creditable—employer should send you a notice annually) — TRICARE and VA drug benefits count for active duty/veterans — Federal Employees Health Benefits Program (FEHBP) — State Pharmaceutical Assistance Programs — Indian Health Service coverage

Notice what's NOT on that list: Medicare Part A and B alone don't help you. Having Medigap doesn't help you. Discount drug cards don't help you. You need actual creditable drug coverage.

**The 63-Day Grace Period**

You get a 63-day gap without penalty. So if your employer coverage ends and you need to enroll in Part D, you have 63 days to do it without incurring any penalty. Don't stretch this. Sixty-three days is two months, not forever. People lose track of time, the 63 days passes, and suddenly there's a penalty.

**Can You Appeal the Penalty?**

Sometimes. If you have documentation proving you had creditable coverage during the disputed period—old insurance cards, a letter from a former employer, documentation from the VA—you can dispute the penalty with Medicare. Call 1-800-MEDICARE and request a reconsideration. Have your documentation ready. This works when the penalty was applied incorrectly, not when you genuinely had a gap.

**The Bottom Line**

Even if you don't take any prescriptions, get a Part D plan when you first become eligible. The cheapest Wellcare plan in your area might be $8-12/month. That's $96-144/year. Missing enrollment and getting hit with 24 months of penalty at 24% of the base premium is $9-12/month extra permanently—on top of your plan premium. The math strongly favors enrolling.

If you're working past 65 with creditable employer coverage, you're fine. Just get a letter from your employer certifying it's creditable, keep it, and enroll in Part D within 63 days of losing that coverage when you retire.

IRMAA stands for Income-Related Monthly Adjustment Amount. If your income is above certain thresholds, you pay a surcharge on top of your plan's regular premium. The surcharge goes directly to Medicare, not your insurance company—they're two separate bills.

In 2026, IRMAA kicks in for individuals with Modified Adjusted Gross Income (MAGI) above $109,000 (or $218,000 for married filing jointly). MAGI is your adjusted gross income plus tax-exempt interest income from your federal tax return.

Important: IRMAA uses income from two years ago. Your 2026 Part D IRMAA is based on your 2024 tax return. So if you had a big income year in 2024—sold a house, took a large IRA distribution, had a one-time capital gain—that income is what determines your 2026 IRMAA.

**2026 Part D IRMAA Surcharge Table**

Individual MAGI / Married Joint MAGI / Monthly Part D Surcharge: — $109,000 - $136,999 / $218,000 - $273,999 / +$14.50/month — $137,000 - $163,999 / $274,000 - $327,999 / +$37.60/month — $164,000 - $191,999 / $328,000 - $383,999 / +$60.60/month — $192,000 - $499,999 / $384,000 - $749,999 / +$83.80/month — $500,000+ / $750,000+ / +$91.00/month

These are surcharges added to your plan's premium. So if your Wellcare Classic plan charges $12/month and you're in the first IRMAA bracket, your total Part D cost is $12 + $14.50 = $26.50/month.

Note also: married filing separately uses a compressed bracket structure. If you file separately and earn over $109,000, you can quickly hit the upper brackets. This catches a lot of people off guard.

**The Cliff Effect**

IRMAA is a cliff surcharge, not a gradual one. $1 of extra MAGI that pushes you into the next bracket triggers the full surcharge increase for that bracket. This is one of the reasons Roth conversions and large IRA distributions require careful planning in the years before and during Medicare enrollment.

**Appealing IRMAA**

You can appeal IRMAA if your income has dropped significantly since the tax year used for the calculation. Life-changing events that qualify: retirement or reduction in work hours, divorce, death of a spouse, loss of income-producing property, loss of pension income, employer settlement. File Form SSA-44 with Social Security and provide documentation of the income change. Appeals based on one-time events like selling a house are generally harder—those are real income events, not life changes.

**How You Pay It**

IRMAA surcharges on Part D are billed by Social Security—usually deducted from your Social Security benefit if you're already receiving it, or billed directly if you're not. You'll get a separate notice from Social Security specifying your IRMAA amount. Pay attention to it. It's easy to assume the surcharge is included in your plan premium and miss it.

Mail-order pharmacy gets recommended constantly in Medicare guides. It's genuinely good for certain situations and genuinely not right for others. Let me be honest about both.

**The Real Advantages**

Cost: Most Part D plans offer 90-day supplies through their mail-order pharmacy at the cost of a 60-day copay. Meaning you get three months of medication for the price of two. On a Tier 1 generic, that might mean $8 instead of $12. On a Tier 3 brand-name drug with a $45 copay per 30-day supply, 90-day by mail might be $90 instead of $135. Annualized, that adds up.

Convenience: Medications show up at your door. If you're on stable maintenance medications—blood pressure, cholesterol, thyroid, diabetes management—and the drugs don't change often, mail-order removes the pharmacy trip. For people with limited mobility or transportation issues, this is real.

The push toward catastrophic: Counterintuitively, paying less per fill doesn't always help you reach the $2,100 cap faster. When your copays are lower, your TrOOP accumulates more slowly. If you're on expensive specialty drugs destined to hit the cap anyway, this doesn't matter. But if you're borderline—spending $1,800-2,000/year—optimizing cost sharing vs. reaching the cap is worth thinking through with a Medicare counselor.

**The Real Disadvantages**

Delay: Mail-order takes time. First fills especially. If you're starting a new medication or need a dose change, waiting 10-14 days for delivery is not always practical. For controlled substances, many mail-order pharmacies have additional restrictions.

New prescriptions: Most mail-order services require you to establish a prescription—often electronically from your doctor. Urgent or new prescriptions don't work well by mail.

Switching: Changing medications, adjusting doses, handling prior authorization issues—all of this is simpler in person at a pharmacy with a pharmacist you can talk to. Mail-order customer service is fine but it's not the same.

Refrigerated or specialty medications: Some specialty drugs require refrigerated shipping and careful handling. Make sure you or someone is home for delivery and check whether the mail-order service has experience with your medication type.

**When Mail Order Makes Sense**

You're on stable maintenance medications. You've been on the same doses for at least 3-6 months. Your plan has a preferred mail-order pharmacy with meaningful cost savings on your specific drugs. You're organized enough to order 3-4 weeks before running out.

Humana Pharmacy, Walgreens mail service (through various plans), OptumRx (UHC), and Express Scripts (through multiple carriers) are the major mail-order operations in 2026. Check your specific plan's mail-order partner before assuming the cost structure applies.

This is where Medicare Part D gets complicated and, frankly, where people get the most frustrated. Let's be clear about what you're dealing with.

**Specialty Drugs in 2026**

Specialty drugs—biologics, injectables, targeted therapies, high-cost oral medications—are typically Tier 4 or Tier 5 on Part D formularies. These include drugs like:

— Humira/Adalimumab (rheumatoid arthritis, Crohn's) — $7,000-9,000/month list price — Dupixent (eczema, asthma) — $3,500-4,000/month — Ozempic/Wegovy (diabetes/weight loss) — significant cost-sharing on most plans — Keytruda/Pembrolizumab (cancer) — often administered in clinical settings under Part B, not D — Revlimid/Lenalidomide (multiple myeloma) — historically $15,000+/month — Tecfidera/Dimethyl fumarate (MS) — $8,000+/month for branded version

Under the $2,100 cap, the catastrophic cost protection is the most important thing here. A patient on Revlimid will hit the $2,100 cap in month one of the year. From February through December, their drug is free. This is the IRA's most significant practical impact.

**Prior Authorization (PA)**

Prior authorization means your insurance plan requires approval before covering a drug. Without approval, you pay full price. PA requirements exist for:

— Specialty drugs (almost universally) — Certain brand-name drugs when a generic alternative exists — Off-label uses (where FDA approval exists for one condition but prescribing for another) — High-risk medications where step therapy protocols apply

In practice, PA means your doctor submits clinical documentation explaining why you need this specific drug. The plan reviews it—usually 72 hours for standard requests, 24 hours for expedited (urgent). They approve or deny.

If denied: you appeal (see the appeal section below). If approved: you fill the prescription. The authorization typically covers a specific timeframe—often 6-12 months—after which it needs renewal.

**Step Therapy**

Step therapy means the plan requires you to try (and fail) on cheaper medications before covering the one your doctor prescribed. Classic example: your doctor prescribes Humira for rheumatoid arthritis. The plan requires you to first try methotrexate and sulfasalazine for 3 months each. If those fail, then they'll approve the biologic.

Step therapy is genuinely the most frustrating Part D barrier for patients on specialty medications. There's an exception process (your doctor can request a step therapy exception based on clinical reasons why the standard step-therapy path isn't appropriate for you), but it requires documentation and physician advocacy.

For 2026, CMS has continued tightening oversight of MA plans' prior authorization practices under the Improving Seniors' Timely Access to Care Act, but these protections apply more directly to medical services than to Part D drug formulary decisions. The fight for specialty drugs at the PA level is still very much alive.

**Biosimilars and What They Mean for Your Drug Costs**

Biosimilars are drugs that are highly similar to existing FDA-approved biologics (they're not identical—biologics are too complex for exact generic copies). As patents on major biologics have expired, biosimilars have flooded the market. This is directly relevant to Part D costs.

In 2026, there are now dozens of biosimilar adalimumab (Humira biosimilar) products on the market. Plans are aggressively moving to prefer biosimilars over branded Humira. The biosimilar versions—Hadlima, Hyrimoz, Cyltezo, Yusimry, Simlandi, others—can be significantly cheaper for plans to cover, and that savings gets passed through as lower cost-sharing or formulary placement.

If your plan is moving you from Humira to a biosimilar adalimumab, clinically they're considered equivalent for most uses. If you have a clinical reason to stay on the branded version, your doctor can request a formulary exception. But expect this shift—it's happening broadly across all major Part D plans.

CMS finalized rules allowing Part D plans to substitute interchangeable biosimilars on formularies within 30 days of adding them. This means your formulary can change mid-year for biosimilar substitutions—with required notice. Pay attention to formulary change notifications.

Your Part D plan denied your drug. Maybe it's not on the formulary. Maybe it requires prior authorization and that was denied. Maybe you're hitting step therapy requirements. Whatever the reason, the denial is not final. Here's how to fight it.

**Step 1: Request a Coverage Determination**

This is actually the starting point—before you even get to an appeal. A coverage determination is your formal request for the plan to cover a drug. It includes:

— Standard: Plan has 72 hours to respond (3 calendar days) — Expedited: Plan has 24 hours if your health would be seriously harmed by waiting

You, your prescriber, or your representative can request a coverage determination. If a pharmacist tells you a drug isn't covered, that can itself be treated as a coverage determination if you ask. The plan must respond in writing with their decision and the reason for any denial.

**Step 2: Redetermination (First Level of Appeal)**

If the coverage determination goes against you, you have 60 days from the denial notice to request a redetermination. This is an internal review by the plan itself—a different set of reviewers than those who made the original decision.

Timelines: — Standard: 7 calendar days (Part D) — Expedited: 72 hours

At this stage: submit additional documentation from your doctor. More clinical information, peer-reviewed research supporting the drug's use for your condition, documentation of failed prior therapies. The more clinical ammunition your prescriber provides, the better your odds here.

**Step 3: Reconsideration by an Independent Review Entity (IRE)**

If the plan's redetermination still denies coverage, you escalate to an Independent Review Entity (IRE)—a third-party organization contracted by CMS to conduct independent reviews. This is outside your plan's control.

You have 60 days from the redetermination denial to file.

Timelines: — Standard: 7 calendar days — Expedited: 72 hours

The IRE is required to be impartial. In practice, the approval rate increases meaningfully at this stage when the clinical documentation is strong. Your doctor's involvement matters enormously here—a detailed letter of medical necessity from a specialist carries significant weight.

**Step 4: Administrative Law Judge (ALJ) Hearing**

If the IRE still denies, you can request a hearing before an ALJ through the Office of Medicare Hearings and Appeals (OMHA). You have 60 days from the IRE decision to request this.

Threshold: The disputed amount must be at least $180 (2026 figure) to qualify for ALJ review.

ALJ hearings are formal proceedings—you can appear in person, by phone, or by video. You can be represented by a lawyer or an advocate. The judge can approve coverage, deny it, or request additional information. ALJ decisions take longer—usually weeks to months—so expedited paths earlier in the process are critical for ongoing medication needs.

**Step 5: Medicare Appeals Council and Federal Court**

Beyond the ALJ, appeals go to the Medicare Appeals Council (administrative level) and ultimately to federal district court for cases meeting the judicial review threshold (currently around $1,810 in dispute).

Realistically: most Part D drug appeals that are going to succeed succeed at Step 2 or Step 3. If you've reached federal court over a Part D drug, you're in rare territory. But the path exists.

**Practical Tips for All Appeals**

Get your doctor to advocate. A prescriber who calls the plan's medical director or submits a detailed peer-reviewed letter is more effective than the patient alone filing paperwork. Specialists carry more weight than primary care in specialty drug appeals.

Document everything. Dates of all communications, names of representatives you spoke with, reference numbers. Create a paper trail.

Use a SHIP counselor. State Health Insurance Assistance Programs (SHIP) provide free Medicare counseling and can help you navigate appeals. Find your local SHIP at shiphelp.org. These people know the process intimately and it costs you nothing.

The question comes up constantly: can I use GoodRx with my Medicare Part D plan? The answer is nuanced and people get it wrong in both directions.

**The Basic Rule**

You cannot use a GoodRx coupon (or any third-party discount card) and your Part D insurance on the same prescription at the same time. Federal law—specifically anti-kickback and coordination of benefits rules—prohibits stacking a coupon on top of a federally funded insurance benefit. Period. If a pharmacy tells you this, they're right.

BUT. You can choose to use GoodRx instead of your Part D plan on a given prescription. Cash transaction, no insurance billed. This is legal and sometimes makes financial sense.

**When GoodRx Might Beat Your Part D Plan**

For certain generic drugs, GoodRx prices can be lower than your plan's copay, especially early in the year before you've met your deductible. Classic scenario: You have a $615 deductible plan. Your doctor prescribes generic atorvastatin 40mg. Your plan would bill you full retail price during the deductible phase—maybe $28-45. GoodRx might show $6-14 for the same drug at the same pharmacy.

In that case, paying cash with GoodRx costs you less. It makes sense. Do it.

**The Critical Trade-off**

When you use GoodRx or any discount card as a cash transaction, that spending does NOT count toward your Part D deductible and does NOT count toward your $2,100 TrOOP.

This is the trade-off you have to evaluate. If you're only taking cheap generics and will never come close to hitting the deductible or cap anyway, using GoodRx whenever it's cheaper is just rational. You're saving money and there's nothing to count toward anyway.

But if you have expensive brand-name drugs and are heading toward the $2,100 cap, using GoodRx on some drugs while billing insurance on others will slow your progress toward catastrophic coverage, where you pay $0. In that case, running everything through your insurance—paying more month-to-month—might get you to the cap faster and save you more overall.

The break-even math depends on your specific drug costs, your plan's cost-sharing structure, and when in the year you'd realistically hit the cap.

**Manufacturer Discount Programs**

This is separate from retail coupons. Major pharmaceutical companies run Patient Assistance Programs (PAPs) or co-pay assistance programs directly. The rules around Medicare are strict here:

Manufacturer co-pay cards (like the kind that say 'pay no more than $10/month for the first year')—these are legal for commercially insured patients but are NOT permitted for Medicare beneficiaries due to anti-kickback regulations. If a manufacturer tries to give you a co-pay card and you're on Medicare, you can't legally use it in conjunction with Medicare coverage. This is heavily enforced.

What IS available: manufacturer Patient Assistance Programs for people who meet income criteria, which provide drugs free or at very low cost outside of the Medicare claim process. For Medicare beneficiaries who can't afford their medications and don't qualify for Extra Help, these programs are worth investigating. NeedyMeds.org and the Partnership for Prescription Assistance are good starting points.

Also: the Manufacturer Discount Program (MDP) replaced the old Coverage Gap Discount Program under the IRA. In 2026, manufacturers of brand-name drugs are required to provide a 10% discount to Part D sponsors during the initial coverage phase and contribute to costs in the catastrophic phase. This discount is embedded in plan negotiations—you don't see it as a direct discount but it affects what plans pay and ultimately how they price tiers.

Medicare Part D in 2026 looks meaningfully different from Medicare Part D three or four years ago. The Inflation Reduction Act's Medicare provisions have been phasing in since 2023. Here's where we actually are in 2026.

**$2,100 Out-of-Pocket Cap (Fully Effective)**

This is the headline change. Before the IRA, there was no out-of-pocket cap on Part D drug spending. The catastrophic phase had cost-sharing—you still paid 5% of drug costs, which for a $15,000/month cancer drug is $750/month. That's devastating. The cap eliminates catastrophic drug spending entirely. For the sickest, most expensive Part D beneficiaries, this is transformative.

**$35 Insulin Cap (Effective since 2023)**

All covered insulin products on any Part D plan are capped at $35/month for a 30-day supply, regardless of which tier the insulin is on or what phase of the benefit you're in. This applies to both standalone PDPs and MA-PD plans. There are now over 20 insulin products covered under this cap across different plans. If you take insulin and aren't paying $35 or less per 30-day supply, something is wrong—check your coverage.

**Free Vaccines (Effective since 2023)**

All ACIP-recommended vaccines for adults are now covered at $0 cost-sharing under Part D. Shingles vaccine (Shingrix), flu, pneumonia, COVID—all free under Part D. No deductible applies. This was a hidden gem of the IRA that didn't get as much attention as the insulin and drug price caps.

**Medicare Drug Price Negotiation**

CMS is now negotiating prices directly with pharmaceutical manufacturers for certain high-volume, high-cost drugs with no generic competition. The first group of 10 drugs had negotiated prices take effect in 2026. These include: Eliquis (apixaban), Jardiance (empagliflozin), Xarelto (rivaroxaban), Januvia (sitagliptin), Farxiga (dapagliflozin), Entresto (sacubitril/valsartan), Enbrel (etanercept), Imbruvica (ibrutinib), Stelara (ustekinumab), and Fiasp/NovoLog insulin products. The negotiated prices reduce what plans pay and are supposed to reduce beneficiary cost-sharing. How much depends on each plan's formulary design.

**The Coverage Gap (Donut Hole) Is Effectively Gone**

The donut hole was a gap in coverage that existed from 2006-2023 where beneficiaries paid 25% of drug costs in the initial coverage phase but a higher percentage in the gap. The IRA collapsed the benefit structure so there's now a flat 25% from deductible to cap. The donut hole language still exists in some explanations of older coverage, but functionally it's gone. You'll still see it mentioned in Medicare materials because the statute technically still describes coverage phases, but the cost-sharing change eliminated its practical effect.